Menu
Back to Journals » Patient Preference and Adherence » Volume 7
Review of depot aripiprazole for schizophrenia
Authors Motiwala FB, Siscoe KS, El-Mallakh RS
Received 29 April 2013
Accepted for publication 3 July 2013
Published 13 November 2013 Volume 2013:7 Pages 1181—1187
DOI https://doi.org/10.2147/PPA.S32972
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Farha Bilal Motiwala, Kim Stasia Siscoe, Rif S El-Mallakh
Mood Disorders Research Program, Department of Psychiatry and Behavioral Sciences, University of Louisville School of Medicine, Louisville, KY, USA
Abstract: Improving outcomes in schizophrenia generally requires an improvement in medication adherence. One of the most effective interventions to improve adherence is the use of depot formulations of antipsychotic medications. A new depot aripiprazole formulation for the treatment of schizophrenia will be available soon. A review of all publically available information on depot aripiprazole as of November 2012 was performed. One peer-reviewed study on depot aripiprazole is published, and the remainder of the data were presented at international scientific meetings. Depot aripiprazole appears to be both safe and effective in the long-term treatment of schizophrenia.
Keywords: aripiprazole, schizophrenia, depot, long-acting injectable, psychosis, treatment
© 2013 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.